Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has 6 years of Other Accumulated Expenses data on file, last reported at $4.4 million in Q4 2022.

• On a quarterly basis, Other Accumulated Expenses fell 91.75% year-over-year to $4.4 million in Q4 2022; TTM through Dec 2022 was $4.4 million, a 91.75% decrease from a year earlier, with the FY2022 full-year figure at $4.4 million, down 91.75% from the prior year.
• Other Accumulated Expenses for Q4 2022 stood at $4.4 million, down from $53.2 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for DNLI reached as high as $53.2 million in Q4 2021 and fell as low as $47000.0 in Q2 2018.
• Historically, Other Accumulated Expenses has averaged $14.1 million across 5 years, with a median of $3.5 million in 2019.
• Across the five-year window, Other Accumulated Expenses jumped 30801.59% in 2018 and plunged 91.75% in 2022, its largest moves.
• Year by year, Other Accumulated Expenses stood at $19.5 million in 2018, then rose by 23.36% to $24.0 million in 2019, then jumped by 96.31% to $47.1 million in 2020, then rose by 12.77% to $53.2 million in 2021, then plunged by 91.75% to $4.4 million in 2022.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $4.4 million in Q4 2022, $53.2 million in Q4 2021, and $47.1 million in Q4 2020.